PRAX - Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress | Benzinga
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will present data from two of its clinical-stage epilepsy programs at the upcoming 35th International Epilepsy Congress (IEC), to be held on September 2-6, 2023 in Dublin, Ireland.
"There remains a great unmet need in epilepsy for anti-seizure medications that restore quality of life to patients and their families, and we are committed to developing best-in-class treatment options for both rare and prevalent epilepsies," said Marcio Souza, president and chief executive officer of Praxis. "Data from our Phase 1 study of PRAX-628 for focal epilepsy support a potentially best-in-class safety profile that could address the limitations of existing therapies, such as poor tolerability and dose-limiting titration requirements. We look forward to presenting data from this program along with data from our PRAX-562 program for children with SCN2A and SCN8A developmental and epileptic encephalopathies."
Presentation Details:
PRAX-628: A Next Generation Functionally Selective Small Molecule with Potent Anticonvulsant Activity
- Session Date/Time: Sunday, September 3, 1:00 p.m. – 3:30 p.m. IST
- Poster Session: Drug Therapy
- Poster number: P031
PRAX-562 is a Well-Tolerated, Next Generation Anti-Seizure Small Molecule with Broad Anticonvulsant Activity in Multiple DEE Mouse Models
- Session Date/Time: Sunday, September 3, 1:00 p.m. – 3:30 p.m. IST
- Poster Session: Pediatric Epileptology
- Poster number: P095
PRAX-562-101: A First-in-Human Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of PRAX-562 in Healthy Volunteers
- Session Date/Time: Monday, September 4, 7:00 p.m. – 7:40 p.m. IST
- Poster Session: Pediatric Epileptology & Mixed
- Poster number: 408
PRAX-562-102: A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRAX-562 in Healthy Volunteers
- Session Date/Time: Monday, September 4, 7:00 p.m. – 7:40 p.m. IST
- Poster Session: Pediatric Epileptology & Mixed
- Poster number: 409
Safety, Tolerability and Pharmacokinetic Findings from a First-in-Human, Randomized, Double-Blinded, Placebo-Controlled Trial of Single and Multiple Ascending Doses of PRAX-628 in Healthy Participants
- Session Date/Time: Tuesday, September 5, 1:00 p.m. – ...